Conditions and Treatments
Learn about the surgery process at American Family Children's Hospital
Comprehensive care within the American Family Children's Hospital Pediatric Hematology, Oncology and Bone Marrow Transplant program means having the ability to readily access the knowledge and skills of many medical and supportive care specialists in the coordinated care of patients with a complex health diagnoses like cancer.
CAR T-cell Therapy for Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
A promising new treatment, known as chimeric antigen receptor or CAR T-cell therapy, is now available at American Family Children’s Hospital for children with acute lymphoblastic leukemia (ALL) that either did not respond to standard therapy or has relapsed a second time. Learn more about CAR T-cell therapy
Cancer Immunotherapy Clinical Trials
Mario Otto, MD, PhD is offering an innovative haploidentical stem cell transplant approach using alpha-beta T cell depletion and NK cell mismatch for children with refractory hematologic malignancies (leukemia and lymphoma) and solid tumors (neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma). We are the only center in the country using Zoledronate to expand gamma-delta T cells, and the only center treating children with refractory solid tumors with this approach. Learn more.
- Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Solid Tumors
Dr. Otto is also opening in summer 2018 a phase I clinical trial only available at AFCH with a radiopharmaceutical called CLR131, which targets pediatric solid tumors like Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, and Osteosarcoma. Learn more.
Ken DeSantes, MD leads a unique clinical trial only available at AFCH, involving infusion of haploidentical (from a parent) natural killer cells with an immunocytokine for children with relapsed or refractory neuroblastoma. The immunocytokine targets GD2, a sugar found on neuroblastoma, and activates immune cells with interleukin-2.
Dr. DeSantes is also offering a multi-center, phase I clinical trial studying Enoblituzumab, an antibody that targets B7-H3 on most pediatric solid tumors. B7-H3 turn offs immune cells, so by blocking this molecule with Enoblituzumab, the patient’s immune system may get “turned on” against the tumor.
All faculty are offering this randomized, phase III trial testing if Brentuximab vedotin, an antibody that targets CD30 on Hodgkin lymphoma cells, can improve outcomes if used with upfront chemotherapy in newly diagnosed patients.
All faculty are offering this randomized, phase II trial testing if Brentuximab vedotin, an antibody that targets CD30 on anaplastic large cell lymphoma cells, has efficacy in newly diagnosed patients.
Treatments for Hematologic and Oncologic Diagnoses
- Radiation Therapy
- Hematopoietic Stem Cell Transplant (Bone marrow, Peripheral, Stem Cell, Cord Blood)
- I-131 MIBG (Metaiodobenzylguadine)
- Transfusions of blood products, including exchange transfusion, erythrocytapheresis and apheresis
Related Services for Pediatric Hematology and Oncology Patients
Multidisciplinary Pediatric Hematology and Oncology Clinics
Multidisciplinary comprehensive clinics are held for the treatment of certain disorders. Oncologists, hematologists, nurse specialists, social workers, physical therapists and geneticists work together with patients, family members and primary care providers to develop a plan for care for children who have specialized needs due to their conditions.
At American Family Children's Hospital, the sub-specialty clinics include: